Increasing evidences indicate that cancer cell resistance to cross-links agents, such as cisplatin, is linked to the functional status of the FA/BRCA pathway [8, 11, 25–27], albeit the exact mechanism of this resistance to the chemical crosslinker remains to be fully elucidated. This evidence concerns the gene FANCA and cancer.